Shots:
- The US FDA has granted clearance to Elecsys pTau217 to measure the phosphorylated Tau (pTau) 217 protein to help rule in or rule out Alzheimer’s-related amyloid pathology in people (≥55yrs.) with signs or complaints of cognitive decline
- In adults aged 55+ with cognitive decline associated with Alzheimer’s disease, Elecsys pTau217 showed high agreement with amyloid PET imaging, offering clinicians a minimally invasive option to assess amyloid pathology
- Elecsys pTau217, developed in collaboration with Eli Lilly, is the first single-assay blood test designed to be used across primary & specialty care settings
Ref: Globenewswire | Image: Roche | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
